Comparative Pharmacology
Head-to-head clinical analysis: PHOSLO versus VELPHORO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLO versus VELPHORO.
PHOSLO vs VELPHORO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium acetate binds phosphate in the gastrointestinal tract, forming insoluble calcium phosphate that is excreted in feces, thereby reducing serum phosphate levels.
Iron-based phosphate binder that forms non-absorbable complexes with dietary phosphate in the gastrointestinal tract, reducing serum phosphate levels.
667 mg (two 667-mg tablets or one 667-mg capsule) orally three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL; maximum 4000 mg/day.
1-2 tablets (500-1000 mg iron) orally three times daily with meals; titrate to achieve serum phosphorus target.
None Documented
None Documented
Not applicable; minimal systemic absorption, local gastrointestinal action
Not applicable (non-absorbed drug acting locally in GI tract; no systemic half-life).
Primarily fecal as unabsorbed drug; minimal renal elimination (<0.5%)
Primarily fecal as unabsorbed drug; negligible renal excretion (<0.1%).
Category C
Category C
Phosphate Binder
Phosphate Binder